Table 4.
Baseline characteristics of propensity-matched patients treated with chemoradiation and surgery versus chemoradiation alone
| Variable | Chemoradiation and surgery (n = 595) | Chemoradiotherapy only (n = 595) | P value | Standardized mean differences |
|---|---|---|---|---|
| Age, y, median (IQR) | 71 (65, 77) | 71 (64, 77) | .601 | 0.027 |
| Female | 59 (9.9%) | 75 (12.6%) | .169 | 0.085 |
| Race | .529 | 0.069 | ||
| White | 566 (95.6%) | 570 (96.4%) | ||
| Black | 8 (1.4%) | 9 (1.5%) | ||
| Other | 18 (3%) | 12 (2%) | ||
| Insured | 582 (98.3%) | 577 (97.6%) | .533 | 0.053 |
| Charlson comorbidity index | .78 | 0.041 | ||
| 0 | 420 (70.6%) | 410 (68.9%) | ||
| 1 | 120 (20.2%) | 124 (20.8%) | ||
| ≥2 | 55 (9.2%) | 61 (10.3%) | ||
| Income above median | 308 (59.9%) | 300 (59.4%) | .917 | 0.044 |
| Education above median | 323 (62.8%) | 312 (61.8%) | .776 | 0.048 |
| Facility type | .435 | 0.102 | ||
| Community program | 63 (10.6%) | 58 (9.8%) | ||
| Comprehensive community | 243 (41%) | 246 (41.4%) | ||
| Integrated network program | 89 (15%) | 108 (18.2%) | ||
| Research/academic | 198 (33.4%) | 182 (30.6%) | ||
| Tumor location | .214 | 0.072 | ||
| Distal esophagus | 572 (96.1%) | 563 (94.6%) | ||
| Mid-esophagus | 23 (3.9%) | 32 (5.4%) | ||
| Clinical T stage | .968 | 0.018 | ||
| T1 | 21 (3.6%) | 22 (3.8%) | ||
| T2 | 74 (12.8%) | 76 (13.1%) | ||
| T3 | 485 (83.6%) | 481 (83.1%) | ||
| Clinical N stage | .531 | 0.025 | ||
| N negative | 179 (30.1%) | 189 (31.8%) | ||
| N positive | 416 (69.9%) | 406 (68.2%) |
IQR, Interquartile range.